# Pharmaceutical Data Collection Strategy

**Prepared by:** Junior Data Engineer  
**Last Updated:** October 2025

---

## 1. Introduction

The purpose of this document is to outline my strategy for collecting pharmaceutical data from multiple, reliable sources. This data will form the foundation for training a specialized medical large language model (AI-Doctor LLM), which requires a high degree of accuracy and quality.

---

## 2. Proposed Data Sources

I have selected a diverse set of sources to cover various aspects of pharmaceutical data, from regulatory information to chemical properties.

### Source 1 (Primary): OpenFDA API
*   **URL:** `https://open.fda.gov/apis/`
*   **About:** The official database of the U.S. Food and Drug Administration. It is the most reliable source for approved drug information in the United States.
*   **Key Data Points:** Brand and generic names, active ingredients, indications for use, warnings, and adverse reactions.
*   **Why is this source important?** It provides official, regulated data, which is crucial for ensuring the accuracy of core medical information.
*   **Access Method:** Free and open REST API.

### Source 2 (For Standardization): RxNorm API
*   **URL:** `https://rxnav.nlm.nih.gov/APIs.html`
*   **About:** A standardized naming system for clinical drugs, maintained by the National Library of Medicine (NLM). It helps link different brand names to the same active ingredient.
*   **Key Data Points:** Unique drug identifiers (RxCUI), mappings between brand and generic names, and dosage forms.
*   **Why is this source important?** It will help us standardize the data we collect from various sources and prevent duplicates caused by different drug names.
*   **Access Method:** Free and open REST API.

### Source 3 (For Chemical Data): PubChem
*   **URL:** `https://pubchem.ncbi.nlm.nih.gov/`
*   **About:** A massive chemical database containing detailed information about chemical substances, including drugs.
*   **Key Data Points:** Chemical structures, molecular formulas, and pharmacological properties.
*   **Why is this source important?** To enrich our dataset with chemical and physical information that could be useful for advanced model training.
*   **Access Method:** Free and open REST API.

### Source 4 (For Deep Clinical Data): DrugBank
*   **URL:** `https://go.drugbank.com/`
*   **About:** A comprehensive knowledge base that links drug data with biological information about their targets in the body.
*   **Key Data Points:** Detailed mechanism of action, drug-drug interactions, and metabolic pathways.
*   **Why is this source important?** It provides deep clinical and biological information not available in other sources, enhancing the model's understanding of complex drug relationships.
*   **Access Method:** Requires a license (a free version is available for academic purposes, whose terms must be verified).

### Source 5 (For Global Context): WHO Essential Medicines List
*   **URL:** `https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists`
*   **About:** A list of essential medicines recommended by the World Health Organization for health systems.
*   **Key Data Points:** Drug classifications based on importance and essential use.
*   **Why is this source important?** It helps prioritize data collection, focusing on the most globally significant and impactful medications.
*   **Access Method:** PDF documents, which will require building a custom parser to extract the data.

---

## 3. Legal and Ethical Considerations

Handling medical data requires extreme care. My plan ensures adherence to the following:
*   **Respect for Terms of Service:** I will comply with the rate limits of each API and use API keys where required.
*   **No Use of Patient Data:** Absolutely no personal or patient-related data will be collected. The focus is solely on publicly available drug information.
*   **Source Documentation:** The source of every piece of information will be documented to ensure transparency and verifiability.
*   **Disclaimer:** It will always be emphasized that this data is for training an AI model and is not a substitute for professional medical advice.

---

## 4. Data Refresh Strategy

Pharmaceutical data changes constantly, so it is vital to have a plan for updates.

### Phase 1: Initial Collection
1.  Begin by collecting core data for the 100 most common drugs from OpenFDA.
2.  Enrich and standardize this data using RxNorm.
3.  Add chemical data from PubChem and drug interactions from DrugBank (if a license is available).

### Phase 2: Continuous Updates
*   **Weekly:** Run the script to check for updates in the primary sources for the collected drugs.
*   **Quarterly:** Perform a full data refresh to ensure all fields are up-to-date.
*   **As Needed:** Trigger updates when new safety alerts are issued by the FDA.

---

## 5. Proposed Data Schema

To organize the data effectively, I propose the following JSON schema for each drug entry. This schema covers essential, clinical, and chemical aspects.

```json
{
  "drug_id": "string (Unique ID)",
  "drug_name": "string (The name used for the search)",
  "generic_name": "string",
  "brand_names": ["string"],
  "drug_class": "string (Pharmaceutical class)",
  "indications": ["string (What the drug is used for)"],
  "mechanism_of_action": "string",
  "dosage_forms": ["string (e.g., tablet, syrup)"],
  "side_effects": {
    "common": ["string"],
    "serious": ["string"]
  },
  "contraindications": ["string (When the drug should not be used)"],
  "drug_interactions": ["string"],
  "metadata": {
    "data_sources": ["OpenFDA", "RxNorm"],
    "last_updated": "ISO 8601 datetime"
  }
}
6. Potential Challenges and Limitations
DrugBank Access: Obtaining a full license for DrugBank may be costly or time-consuming.
WHO Data: Extracting data from PDF files is a complex process and may be prone to errors.
Data Conflicts: There may be conflicting information between different sources, which will require setting priority rules or flagging the data for manual review.